Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 6/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247074 | 0.89 | CSNK1A1 (0.45) | CSNK1A1TYRO3DYRK1BPTGESPARP1 | |
| SCHEMBL4243724 | 0.87 | CSNK1A1 (0.39) | CSNK1A1TYRO3DYRK1BPTGESPARP1 | |
| SCHEMBL4239128 | 0.84 | ADRA2A (0.42) | PTGESADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4239784 | 0.82 | FFAR2 (0.43) | CSNK1A1TYRO3DYRK1BPTGESFFAR2 | |
| SCHEMBL4240809 | 0.80 | PTGES (0.35) | CSNK1A1TYRO3DYRK1BPTGESADRA2A | |
| SCHEMBL4242690 | 0.78 | PTGES (0.39) | CSNK1A1TYRO3DYRK1BPTGESFFAR2 | |
| SCHEMBL4239412 | 0.78 | PTGES (0.41) | P2RX7PTGESCYP3A4CD38AURKA | |
| SCHEMBL4242105 | 0.74 | IKBKB (0.38) | PTGESFFAR2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4240368 | 0.71 | PTGES (0.37) | PTGES | |
| SCHEMBL4243618 | 0.71 | PTGES (0.37) | PTGESADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CSNK1A1 837/4885TYRO3 3651/4885DYRK1B 4348/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CSNK1A1 837/4885TYRO3 3651/4885DYRK1B 4348/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CSNK1A1 837/4885TYRO3 3651/4885DYRK1B 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.